Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Liabilities and Shareholders Equity: 2009-2024

Historic Liabilities and Shareholders Equity for Gyre Therapeutics (GYRE) over the last 15 years, with Dec 2024 value amounting to $125.4 million.

  • Gyre Therapeutics' Liabilities and Shareholders Equity rose 27.26% to $159.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $567.2 million, marking a year-over-year increase of 17.02%. This contributed to the annual value of $125.4 million for FY2024, which is 7.61% up from last year.
  • According to the latest figures from FY2024, Gyre Therapeutics' Liabilities and Shareholders Equity is $125.4 million, which was up 7.61% from $116.5 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Liabilities and Shareholders Equity ranged from a high of $125.4 million in FY2024 and a low of $55.7 million during FY2021.
  • For the 3-year period, Gyre Therapeutics' Liabilities and Shareholders Equity averaged around $108.9 million, with its median value being $116.5 million (2023).
  • As far as peak fluctuations go, Gyre Therapeutics' Liabilities and Shareholders Equity slumped by 41.31% in 2021, and later surged by 52.26% in 2022.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Liabilities and Shareholders Equity stood at $94.8 million in 2020, then slumped by 41.31% to $55.7 million in 2021, then soared by 52.26% to $84.8 million in 2022, then soared by 37.50% to $116.5 million in 2023, then increased by 7.61% to $125.4 million in 2024.